None listed
Conditions
Interventions
Oral ingestion of the test product containing Curcuma longa (3 tablets per a day
12 weeks)
Oral ingestion of the test product not containing Curcuma longa (3tablets per a day
Sponsors
House Wellness Foods Corporation Research and Development Institute
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Healthy males and females over the age of 19 years (2) Participants whose AST and ALT levels are <51 U/L (3) Participants whose BMI are >=24 and <30
Exclusion criteria
Exclusion criteria: (1) Participants whose HCV antibody or HbsAg are positive (2) Participants whose systolic blood pressure are lower than 90 mmHg (3) Participants who are possibly pregnant, pregnant, or lactating (4) Participants who have made a blood donation of 200 mL within the last one month prior to this study (5) Male participants who have made a blood donation of 400 mL within the last three months prior to this study (6) Female participants who have made a blood donation of 400 mL within the last four months prior to this study (7) Male participants who have made a blood donation over an amout (1,200 mL minus the estimated volume of blood sampling during the study) within the last one year prior to this study (8) Female participants who have made a blood donation over an amout (800 mL minus the estimated volume of blood sampling during the study) within the last one year prior to this study (9) Participants who are participating in another clinical study or had finished another clinical study within the last four weeks (10) Participants who have heart disease, liver disease, or kidney disease (11) Participants who have any history of cardiovascular disease (12) Participants who are diabetes mellitus (13) Participants have medication or food allergy (14) Participants who have excessive alcohol-drinking or smoking habit (15) Participants who have extremely irregular dietary habits (16) Participants who consecutively intake pharmaceutical or healthcare food which is possible to influence the result of this study (17) Participants judged as unsuitable for the study by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| At 0, 4, 8, 12 weeks in the intervention and 4 weeks after the intervention. [1]Aspartate aminotransferase (AST) [2]Alanine aminotransferase (ALT) | — |
Secondary
| Measure | Time frame |
|---|---|
| At 0, 4, 8, 12 weeks in the intervention and 4 weeks after the intervention. [1]Gammma glutamyltransferase (Gammma-GTP) [2]Questionnaire survey (POMS-Brief) At 0, 12 weeks in the intervention. [3]Tumor Necrosis Factor-alpha (TNF-alpha) [4]Interleukin-6 (IL-6) [5]C-reactive protein (CRP) [6]Prostaglandin E2 (PGE2) [7]Serum amyloid A protein (SAA) | — |
Countries
Japan
Contacts
Public ContactKengo Kawasaki
House Wellness Foods Corporation Research and Development Institute
Outcome results
None listed